(Q37259594)

19 August 2017

1 reference

title

Strategies used for MUC1 immunotherapy: preclinical studies (English)

1 reference

19 August 2017

1 reference

Vasso Apostolopoulos

2

0 references

author name string

Choon-Kit Tang

series ordinal

1

1 reference

19 August 2017

publication date

1 September 2008

1 reference

Expert Review of Vaccines

19 August 2017

published in

1 reference

19 August 2017

volume

7

1 reference

19 August 2017

issue

7

1 reference

19 August 2017

page(s)

951-962

1 reference

Summary report on the ISOBM TD-4 Workshop: analysis of 56 monoclonal antibodies against the MUC1 mucin. San Diego, Calif., November 17-23, 1996.

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.951

MUC‐1 Epithelial Tumor Mucin‐Based Immunity and Cancer Vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.951

MCF7 side population cells with characteristics of cancer stem/progenitor cells express the tumor antigen MUC1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.951

MUC1 peptide epitopes associated with five different H-2 class I molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.951

A glycopeptide in complex with MHC class I uses the GalNAc residue as an anchor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.951

Definition of MHC-restricted CTL epitopes from non-variable number of tandem repeat sequence of MUC1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.951

MUC1-derived glycopeptide libraries with improved MHC anchors are strong antigens and prime mouse T cells for proliferative responses to lysates of human breast cancer tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.951

Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.951

O-glycosylated versus non-glycosylated MUC1-derived peptides as potential targets for cytotoxic immunotherapy of carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.951

Dendritic cells: activation and maturation--applications for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.951

Ex vivo targeting of the macrophage mannose receptor generates anti-tumor CTL responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.951

Oxidative/reductive conjugation of mannan to antigen selects for T1 or T2 immune responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.951

The immunogenicity of MUC1 peptides and fusion protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.951

Delivery of tumor associated antigens to antigen presenting cells using penetratin induces potent immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.951

Oxidised mannan antigen conjugates preferentially stimulate T1 type immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.951

Mannan derivatives induce phenotypic and functional maturation of mouse dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.951

Strategies used for MUC1 immunotherapy: human clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.951

Keyhole limpet hemocyanin (KLH): a biomedical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.951

Immunogenicity of synthetic peptides related to the core peptide sequence encoded by the human MUC1 mucin gene: effect of immunization on the growth of murine mammary adenocarcinoma cells transfected with the human MUC1 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.951

Comparison of the effect of different immunological adjuvants on the antibody and T-cell response to immunization with MUC1-KLH and GD3-KLH conjugate cancer vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.951

Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and GD3-KLH conjugates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.951

Liposomal vaccines: clinical status and immunological presentation for humoral and cellular immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.951

Liposome adjuvants prepared from the total polar lipids of Haloferax volcanii, Planococcus spp. and Bacillus firmus differ in ability to elicit and sustain immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.951

Liposomal formulations of synthetic MUC1 peptides: effects of encapsulation versus surface display of peptides on immune responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.951

Use of a liposome antigen delivery system to alter immune responses in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.951

Immunogenicity and antitumor activity of a liposomal MUC1 peptide-based vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.951

Mucin 1-specific immunotherapy in a mouse model of spontaneous breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.951

Characterization of the MUC1.Tg/MIN transgenic mouse as a model for studying antigen-specific immunotherapy of adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.951

MUC1-specific immune therapy generates a strong anti-tumor response in a MUC1-tolerant colon cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.951

Biodegradable nanoparticle mediated antigen delivery to human cord blood derived dendritic cells for induction of primary T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.951

Characterization of poly(D,L-lactic-co-glycolic acid) based nanoparticulate system for enhanced delivery of antigens to dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.951

Promising particle-based vaccines in cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.951

Mucin-type O-glycosylation and its potential use in drug and vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.951

Protection against MUC1 expressing mouse tumours by intra-muscular injection of MUC1 cDNA requires functional CD8+ and CD4+ T cells but does not require the MUC1 tandem repeat domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.951

Long-term tumor growth suppression in mice immunized with naked DNA of the human tumor antigen mucin (MUC1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.951

A MUC1/IL-18 DNA vaccine induces anti-tumor immunity and increased survival in MUC1 transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.951

Structure and design of polycationic carriers for gene delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.951

Mannan-mediated gene delivery for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.951

Th2-dominated antitumor immunity induced by DNA immunization with the genes coding for a basal core peptide PDTRP and GM-CSF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.951

Intramuscular immunization with plasmid coexpressing tumour antigen and Flt-3L results in potent tumour regression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.951

Human sodium iodide symporter gene adjunctive radiotherapy to enhance the preventive effect of hMUC1 DNA vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.951

Immunization with a vaccine that combines the expression of MUC1 and B7 co-stimulatory molecules prolongs the survival of mice and delays the appearance of mouse mammary tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.951

Getting into the groove: unusual features of peptide binding to MHC class I molecules and implications in vaccine design

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.951

Mimics and cross reactions of relevance to tumour immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.951

Crystal structure of a non-canonical high affinity peptide complexed with MHC class I: a novel use of alternative anchors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.951

Crystal structure of a non-canonical low-affinity peptide complexed with MHC class I: a new approach for vaccine design

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.951

Dendritic cell-based vaccines and therapies for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.951

Dendritic cell fusion vaccines for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.951

Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.951

Cell fusion: from hybridoma to dendritic cell-based vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.951

Clinical development of MVA-based therapeutic cancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.951

MUC1/X protein immunization enhances cDNA immunization in generating anti-MUC1 alpha/beta junction antibodies that target malignant cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.951

PankoMab: a potent new generation anti-tumour MUC1 antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.951

Combination chemotherapy and radiation of human squamous cell carcinoma of the head and neck augments CTL-mediated lysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.951

Induction of T1 (cytotoxic lymphocyte) and/or T2 (antibody) responses to a mucin-1 tumour antigen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.951

Tumor-Associated Tn-MUC1 Glycoform Is Internalized through the Macrophage Galactose-Type C-Type Lectin and Delivered to the HLA Class I and II Compartments in Dendritic Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.951

Cell-mediated immune responses to MUC1 fusion protein coupled to mannan

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.951

A preclinical study comparing approaches for augmenting the immunogenicity of a heptavalent KLH-conjugate vaccine against epithelial cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.951

Oxidized and reduced mannan mediated MUC1 DNA immunization induce effective anti-tumor responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.951

MUC1 cross-reactive Galα(l,3)Gal antibodies in humans switch immune responses from cellular to humoral

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.951

Selection and characterization of MUC1-specific CD8+ T cells from MUC1 transgenic mice immunized with dendritic-carcinoma fusion cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.951

21 January 2018

Identifiers

DOI

10.1586/14760584.7.7.951

1 reference

19 August 2017

1 reference